PFE monthly performance report
Check PFE's monthly returns, drawdown, and seasonality trends — updated every month.
PFE monthly report
—
Key takeaways
- Pfizer (PFE) closed September 2026 at $27.66, down 2.81% for the month and +14.53% over the trailing 12 months.
- Year-to-date, PFE is +11.08%, underperforming the S&P 500 which has returned +11.70% YTD.
- The stock is trading +5.47% versus its 200-day moving average ($26.22), a bullish technical signal.
- Over the past three years, PFE has underperformed the S&P 500 by −89.47%, with a relative strength index reading of 47.9.
- Win rate over the trailing 39 months stands at 33.3% — 13 positive months versus 26 negative months.
Pfizer ended September 2026 at $27.66, posting a monthly return of −2.81%. The S&P 500 returned −0.70% over the same window, leaving relative performance at −2.11%.
The current quarter stands at +14.87% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +5.47% versus the 200-day moving average ($26.22).
Year-to-date, PFE is +11.08% against SPY +11.70%, a gap of −0.61%. The stock is currently −4.92% below its 52-week high, with maximum 3-year drawdown at −36.48%.
| Period | PFE | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.07% | −0.12% | +0.19% |
| 1 Week | −0.22% | −0.34% | +0.12% |
| 1 Month | −2.81% | −0.70% | −2.11% |
| 3 Months | +6.38% | +2.80% | +3.59% |
| 6 Months | +2.98% | +13.85% | −10.87% |
| YTD | +11.08% | +11.70% | −0.61% |
| 12 Months | +14.53% | +15.01% | −0.48% |
| 3 Years | −17.78% | +71.69% | −89.47% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2026 | +13.79% |
| #2 | May 2024 | +11.87% |
| #3 | Jul 2024 | +9.15% |
| #4 | Aug 2025 | +6.31% |
| #5 | Jan 2026 | +6.18% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | −8.02% |
| #2 | Oct 2023 | −7.87% |
| #3 | Apr 2024 | −7.68% |
| #4 | Nov 2024 | −7.39% |
| #5 | Sep 2023 | −6.25% |
| Quarter | Return |
|---|---|
| Q2 2025 | −4.34% |
| Q3 2025 | +5.12% |
| Q4 2025 | −2.28% |
| Q1 2026 | +12.77% |
| Q2 2026 | −14.25% |
| Q3 2026 (QTD) | +14.87% |
| Year | Return |
|---|---|
| 2023 | −43.81% |
| 2024 | −7.85% |
| 2025 | −6.14% |
| 2026 | +11.08% |
| Metric | Value |
|---|---|
| 52-Week High | $29.09 (2026-09-01) |
| 52-Week Low | $23.58 (2025-09-25) |
| Current Price | $27.66 |
| 200-Day Moving Average | $26.22 |
| Price vs 200DMA | +5.47% |
| 3-Year Maximum Drawdown | −36.48% (2025-04-10) |
| Current Drawdown from 52W High | −4.92% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 47.9 |
| 3-Year Excess Return vs S&P 500 | −89.47% |
| RS Peak | 106 (Oct 2023) |
| RS Trough | 41.6 (Jul 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was PFE's return for this report period?
PFE returned −2.81% in the latest monthly window ending 2026-09-18.
Has PFE outperformed SPY year to date?
YTD PFE: +11.08% vs SPY: +11.70%.
What is PFE's 12-month return?
+14.53% over the trailing 12 months.
Is PFE above or below its 200-day moving average?
Price is +5.47% versus 200DMA ($26.22).
What is the maximum drawdown in the 3-year window?
−36.48% on 2025-04-10.